Stay updated with breaking news from Peter Greenleaf. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aurinia Pharmaceuticals , the kidney therapies developer that was pushed by activist hedge fund MKT Capital to sell itself, failed to attract binding offers and will embark on share buybacks and cost...
Total net revenue was $45.1 million and $175.5 million, and net product revenue was $42.3 million and $158.5 million, for the fourth quarter and full year 2023, respectively $350.7 million of...
A survey of North American equities heading in both directions
Aurinia Pharmaceuticals, Inc. (NASDAQ: AUPH) shares are trending on social media Friday. The company provided its preliminary, unaudited fourth-quarter and fiscal year 2023 financial results. What To Know:
Preliminary unaudited total net revenue for the fourth quarter and full year 2023 of approximately $45 million and $176 million Preliminary unaudited net product revenue for the fourth quarter and...